Patents by Inventor Carlton D. Donald

Carlton D. Donald has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TARGETING PAX2 FOR THE TREATMENT OF BREAST CANCER
    Publication number: 20210213136
    Abstract: The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.
    Type: Application
    Filed: March 2, 2021
    Publication date: July 15, 2021
    Inventor: Carlton D. Donald
  • Targeting PAX2 for the treatment of breast cancer
    Patent number: 11033628
    Abstract: The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: June 15, 2021
    Assignee: PHIGENIX, INC.
    Inventor: Carlton D. Donald
  • TARGETING PAX2 FOR THE TREATMENT OF BREAST CANCER
    Publication number: 20200085967
    Abstract: The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.
    Type: Application
    Filed: September 17, 2019
    Publication date: March 19, 2020
    Inventor: Carlton D. Donald
  • TARGETING EN2, PAX2, AND/OR DEFB1 FOR TREATMENT OF PROSTATE CONDITIONS
    Publication number: 20140336130
    Abstract: The present invention relates to the compositions and use of compositions for treating a prostate condition in a subject. The use of composition comprises administering to the subject a subject effective amount of a pharmaceutical composition having a first agent that inhibits EN2 expression and/or EN2 activity and a second agent that inhibits PAX2 expression and/or PAX2 activity. The pharmaceutical composition may further comprise a third agent that enhances DEFB1 expression or activity.
    Type: Application
    Filed: December 5, 2011
    Publication date: November 13, 2014
    Applicant: PHIGENIX, INC.
    Inventor: Carlton D. Donald
  • COMPOSITIONS AND METHODS FOR MONITORING AND DETECTING CANCEROUS CONDITIONS
    Publication number: 20140323349
    Abstract: A method for monitoring or detecting a prostate condition in a subject comprises determining Engrailed-2 (EN2) gene, Paired Box 2 (PAX2) gene, and/or ? defensin-1 (DEFB1) gene expression levels in a biological sample from the subject. The expression levels of EN2, PAX2 and/or DEFB1 gene are correlated with cancerous, pre-cancerous, or non-cancerous prostate conditions.
    Type: Application
    Filed: December 5, 2011
    Publication date: October 30, 2014
    Inventor: Carlton D. Donald
  • Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
    Patent number: 8735365
    Abstract: Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: May 27, 2014
    Assignee: Phigenix, Inc.
    Inventor: Carlton D. Donald
  • TARGETING EN2, PAX2, AND/OR DEFB1 FOR TREATMENT OF PROSTATE CONDITIONS
    Publication number: 20140135378
    Abstract: The present invention relates to methods and compositions for treating a prostate condition in a subject. The method comprises administering to the subject a subject effective amount of a pharmaceutical composition having a first agent that inhibits EN2 expression and/or EN2 activity and a second agent that inhibits PAX2 expression and/or PAX2 activity. The pharmaceutical composition may further comprise a third agent that enhances DEFB1 expression or activity.
    Type: Application
    Filed: January 16, 2014
    Publication date: May 15, 2014
    Applicant: Phigenix, Inc.
    Inventor: Carlton D. DONALD
  • Targeting EN2, PAX2, and/or DEFB1 for treatment of prostate conditions
    Patent number: 8722643
    Abstract: The present invention relates to methods and compositions for treating a prostate condition in a subject. The method comprises administering to the subject a subject effective amount of a pharmaceutical composition having a first agent that inhibits EN2 expression and/or EN2 activity and a second agent that inhibits PAX2 expression and/or PAX2 activity. The pharmaceutical composition may further comprise a third agent that enhances DEFB1 expression or activity.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: May 13, 2014
    Assignee: Phigenix, Inc.
    Inventor: Carlton D. Donald
  • Detecting PAX2 for the diagnosis of breast cancer
    Patent number: 8722367
    Abstract: A method for monitoring breast conditions in a subject is disclosed. The method comprises determining a Paired Box 2 gene-to-beta defensin-1 gene (PAX2-to-DEFB1) expression ratio (the “Donald Predictive Factor” or “DPF”) in cells obtained from the breast of the subject, wherein the PAX2-to-DEFB1 expression ratio is correlated with breast conditions. Also disclosed is a kit for monitoring breast conditions and determining drug resistance.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: May 13, 2014
    Assignee: Phigenix, Inc.
    Inventor: Carlton D. Donald
  • Targeting PAX2 for the treatment of breast cancer
    Patent number: 8653021
    Abstract: The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: February 18, 2014
    Assignee: Phigenix, Inc.
    Inventor: Carlton D. Donald
  • Targeting PAX2 for the treatment of breast cancer
    Patent number: 8633149
    Abstract: The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: January 21, 2014
    Assignee: Phigenix, Inc.
    Inventor: Carlton D. Donald
  • Detecting PAX2 for the diagnosis of breast cancer
    Patent number: 8623617
    Abstract: A method for monitoring breast conditions in a subject is disclosed. The method comprises determining a Paired Box 2 gene-to-beta defensin-1 gene (PAX2-to-DEFB1) expression ratio (the “Donald Predictive Factor” or “DPF”) in cells obtained from the breast of the subject, wherein the PAX2-to-DEFB1 expression ratio is correlated with breast conditions. Also disclosed is a kit for monitoring breast conditions and determining drug resistance.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: January 7, 2014
    Assignee: Phigenix, Inc.
    Inventor: Carlton D. Donald
  • TARGETING EN2, PAX2, AND/OR DEFB1 FOR TREATMENT OF PROSTATE CONDITIONS
    Publication number: 20130296403
    Abstract: The present invention relates to methods and compositions for treating a prostate condition in a subject. The method comprises administering to the subject a subject effective amount of a pharmaceutical composition having a first agent that inhibits EN2 expression and/or EN2 activity and a second agent that inhibits PAX2 expression and/or PAX2 activity. The pharmaceutical composition may further comprise a third agent that enhances DEFB1 expression or activity.
    Type: Application
    Filed: June 7, 2013
    Publication date: November 7, 2013
    Inventor: Carlton D. DONALD
  • Targeting PAX2 for the treatment of breast cancer
    Patent number: 8461101
    Abstract: The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: June 11, 2013
    Assignee: Phigenix, Inc.
    Inventor: Carlton D. Donald
  • Targeting EN2, PAX2, and/or DEFB1 for treatment of prostate conditions
    Patent number: 8461126
    Abstract: The present invention relates to methods and compositions for treating a prostate condition in a subject. The method comprises administering to the subject a subject effective amount of a pharmaceutical composition having a first agent that inhibits EN2 expression and/or EN2 activity and a second agent that inhibits PAX2 expression and/or PAX2 activity. The pharmaceutical composition may further comprise a third agent that enhances DEFB1 expression or activity.
    Type: Grant
    Filed: December 5, 2011
    Date of Patent: June 11, 2013
    Assignee: Phigenix, Inc.
    Inventor: Carlton D. Donald
  • Compositions and methods for diagnosing, treating, and preventing prostate conditions
    Patent number: 8445444
    Abstract: Disclosed are compositions and methods for diagnosing, preventing, and treating prostate cancer and prostate intraepithelial neoplasia (PIN).
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: May 21, 2013
    Assignee: Phigenix, Inc.
    Inventor: Carlton D. Donald
  • Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
    Patent number: 8431546
    Abstract: Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: April 30, 2013
    Assignee: Phigenix, Inc.
    Inventor: Carlton D. Donald
  • Targeting PAX2 for the treatment of breast cancer
    Patent number: 8394780
    Abstract: The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.
    Type: Grant
    Filed: March 17, 2011
    Date of Patent: March 12, 2013
    Assignee: Phigenix, Inc.
    Inventor: Carlton D. Donald
  • DETECTING PAX2 FOR THE DIAGNOSIS OF BREAST CANCER
    Publication number: 20130023424
    Abstract: A method for monitoring breast conditions in a subject is disclosed. The method comprises determining a Paired Box 2 gene-to-beta defensin-1 gene (PAX2-to-DEFB1) expression ratio (the “Donald Predictive Factor” or “DPF”) in cells obtained from the breast of the subject, wherein the PAX2-to-DEFB1 expression ratio is correlated with breast conditions. Also disclosed is a kit for monitoring breast conditions and determining drug resistance.
    Type: Application
    Filed: September 7, 2012
    Publication date: January 24, 2013
    Applicant: PHIGENIX, INC.
    Inventor: Carlton D. DONALD
  • DETECTING PAX2 FOR THE DIAGNOSIS OF BREAST CANCER
    Publication number: 20130023425
    Abstract: A method for monitoring breast conditions in a subject is disclosed. The method comprises determining a Paired Box 2 gene-to-beta defensin-1 gene (PAX2-to-DEFB1) expression ratio (the “Donald Predictive Factor” or “DPF”) in cells obtained from the breast of the subject, wherein the PAX2-to-DEFB1 expression ratio is correlated with breast conditions. Also disclosed is a kit for monitoring breast conditions and determining drug resistance.
    Type: Application
    Filed: September 7, 2012
    Publication date: January 24, 2013
    Applicant: Phigenix, Inc.
    Inventor: Carlton D. DONALD